Sugden, Bradley M. http://orcid.org/0000-0001-7552-7497
Grimm, Sabine E.
Wolff, Robert
Armstrong, Nigel
Otten, Thomas
Abu-Zahra, Teebah
Perry, Mark
Patel, Mubarak
Chen, Jiongyu
Noake, Caro
Joore, Manuela
Witlox, Willem J. A.
Funding for this research was provided by:
Health Technology Assessment Programme
Article History
Accepted: 7 April 2024
First Online: 7 May 2024
Declarations
:
: This project was funded by the National Institute for Health Research Health Technology Assessment programme. Please visit the HTA programme website for further project information (). This summary of the EAG report was compiled after NICE issued the final appraisal document. The views and opinions expressed herein are those of the authors and do not necessarily reflect those of NICE or the Department of Health.
: Bradley M. Sugden, Sabine E. Grimm, Robert Wolff, Nigel Armstrong, Thomas Otten, Teebah Abu-Zahra, Mark Perry, Mubarak Patel, Jiongyu Chen, Caro Noake, Manuela Joore and Willem J.A. Witlox have no conflicts of interest that are directly relevant to the content of this article.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: The draft of this manuscript was written by BS, WW, SG, RW, NA, MPa, JC and CN. All authors had the chance to comment on previous versions of the manuscript and provided their approval for the final version to be published. RW, NA, MPe, MPa and CN critiqued the clinical effectiveness data reported, and the literature search conducted by the company and contributed to the writing of the EAG report. BS, SG, TO, TA-Z, MJ and WW critiqued the mathematical model provided and the cost-effectiveness analyses submitted by the company and contributed to the writing of the EAG report. BS acts as the overall guarantor for the article.